References
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group (2010) Effect of Dutasteride on the risk of prostate cancer. N Eng J Med 362:1192–1202
Andriole GL, Crawford ED, Grubb RL 3rd et al (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132
Katelaris NC, Bolton DM, Weerakoon M et al (2015) Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J Urol 56(5):337–345
Prostate-Specific Antigen (PSA) testing in asymptomatic men (2014) https://www.nhmrc.gov.au/health-topics/testing-prostate-cancer/prostate-specific-antigen-psa-testing-expert-advisory-group
Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL (2009) A framework for the identification of men at increased risk for prostate cancer. J Urol 182:2112–2120
Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8(3):439–443
Schröder FH, Hugosson J, Carlsson S et al (2012) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 62(5):745–752
Schröder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027–2035
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Eng J Med 350:2239–2246
Vertosick EA, Poon BY, Vickers AJ (2014) Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192(3):724–729
See Also
(2012) 5-Alpha reductase. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 147–148. doi:10.1007/978-3-642-16483-5_6815
(2012) Confounding. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 968. doi:10.1007/978-3-642-16483-5_1304
(2012) Dutasteride. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1171. doi:10.1007/978-3-642-16483-5_6814
(2012) Finasteride. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1407. doi:10.1007/978-3-642-16483-5_2191
(2012) PSA. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 3111–3112. doi:10.1007/978-3-642-16483-5_6738
(2012) Transrectal ultrasound. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3775. doi:10.1007/978-3-642-16483-5_6782
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Gardiner, R.A., Frydenberg, M. (2015). Prostate Cancer Diagnosis. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6825-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_6825-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences